Related Experiment Video
Updated: Jun 24, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Bevacizumab-associated hypertension: etiology, incidence, and management
1aDepartment of Gastrointestinal and Endocrine Surgery, UT Southwestern Medical Center/VA North Texas Health Care System bDepartment of Medicine, Division of Hematology/Oncology, Dallas, Texas, USA.
Abstract:
Bevacizumab (Avastin) is a recently developed monoclonal antibody, which targets the vascular endothelial growth factor signaling pathway, and is currently used in combination with cytotoxic agents as first-line or second-line therapy for patients with metastatic colon cancer. Hypertension is a known risk factor associated with the use of bevacizumab. In this report, we describe the incidence, etiology, and management of patients with this complication.
Related Concept Videos
Hypertension V: Nursing Management
Hypertension and Regulation of Blood Pressure
Venous Thrombosis III: Interprofessional Care
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension II: Pathophysiology
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...